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ABSTRACT
Objective: This study aimed to evaluate the use and potential drug interactions of proton-pump inhibitor (PPI) in outpatients.
Methods: This study is a retrospective descriptive analysis of prescriptions and medical records from outpatients in Gatot Soebroto Army Hospital 
selected by purposive sampling who received PPI with one or more other drugs from July to December 2015. The analysis was conducted on 400 
prescriptions from 192 patients.
Results: Data showed that 100% of the PPI therapy utilized was appropriate for the patients’ condition, 79.00% was appropriate for the indication, 
79.00% was appropriate for the dosage, 79.00% had an appropriate administration duration, and 83.75% was given the appropriate drug. The 
potential of PPI interactions with other drugs was found in 324 prescriptions (81.00%) from 475 cases. Of all the cases, 42 were considered major 
interactions, 138 were moderate interactions, and 295 cases had minor interactions. There were 14 drugs that could potentially interact with PPI, such 
as mycophenolate mofetil, clopidogrel, cilostazol, warfarin, iron, levothyroxine, propranolol, cyclosporine, simvastatin, atorvastatin, cyanocobalamin, 
sucralfate, theophylline, and antacids.
Conclusion: PPI use in outpatients at the Gatot Soebroto Army Hospital was not entirely appropriate and had a large number of potential drug 
interactions with concurrent drugs.
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INTRODUCTION
Since their discovery in 1989, proton-pump inhibitors (PPIs) have 
been widely used for the treatment of various gastric acid-related 
disorders. In the case of gastrointestinal (GI) diseases, PPI is preferred 
because of their high success rate as a treatment. PPI use has increased 
by 456% since the 1990s, suggesting that PPI has become one of the 
most commonly prescribed drugs in the world [1]. In 2009, PPI was the 
third highest prescribed drug in the United States with 119.4 million 
prescriptions [2]. In Australia, PPI was in the top ten of the highest 
prescribed medications in 2013.
Several clinical trials have shown that PPI is safe and well tolerated when 
used appropriately; however, excessive use and increased drug abuse 
may result in increased side effects [1]. Sheen and Triadafilopoulos 
showed that 75% of long-term PPI users of 60–89 years old experienced 
Vitamin B12 deficiency as a side effect of the antiviral drug [3]. Van der 
Hoorn et al. agreed that there was an increased risk of fractures due to 
osteoporosis associated with long-term use of PPI [4].
PPI have often been used in conjunction with other classes of drugs 
because of their extensive use, thus increasing the potential for drug 
interactions. According to Setiawati, the level of polypharmacy has 
influenced the potential for drug interactions [5]. The potential of 
drugs interactions can increase when the consumption of the drugs 
higher. However, not all potential interactions that occurred were 
clinically meaningful interactions [5]. The clinical significance of a drug 
interaction can be seen from its severity as a minor, moderate, or major 
interaction [6].
This study aimed to evaluate the use of PPI at Gatot Soebroto Army Hospital 
in Jakarta, Indonesia, based on assessment of the patient’s condition, 
indications, dosage, administration duration, and drug selection, as well as 
a description the potential drug interaction of PPI to increase the alertness 
of health workers to the adverse effects of drug interactions.
METHODS
This research was a retrospective descriptive analysis and was conducted 
in a pharmacy installation and the medical record room of Gatot Soebroto 
Army Hospital in Central Jakarta from February to April 2016. The data 
used were secondary data taken from the prescriptions and medical 
records of outpatients from July to December 2015. Purposive sampling 
was used to choose the subjects, and the data include all Social Insurance 
Administration Organization outpatients from July to December 2015 
who received PPI with one or more other drugs.
The evaluation of the use of PPI was based on an appropriate assessment 
of the patients’ condition, indications, dosage, administration 
duration, and drug selection by comparing the data obtained from 
the Drug Information Handbook, 17th edition, Pharmacotherapy: 
A Pathophysiologic Approach, 6th Edition, Informasi Obat Nasional 
Indonesia 2014, and related journals. The potential drug interactions 
of PPI were traced electronically using Micromedex Solutions 
(2016, Truven Health Analytics, Inc., Ann Arbor, MI) and traced manually 
based on Stockley’s Drug Interaction 8th edition, Drug Interactions by 
Hansten, Drug Interaction Facts, 5th edition, and related journals.
Microsoft Excel (2010) was used to perform a univariate analysis. This 
analysis aimed to explain the characteristics of research variables 
through the frequency and percentage of the occurrence of each 
variable including the distribution of patient characteristics sex, age, 
diagnosis, and description of PPI therapy that consist of classes of PPI, 
dosage regimen, and administration duration, evaluation of the rational 
use of PPI (assessment of the patient’s condition, indication of disease, 
dosage, administration duration, and drug selection), and potential 
drug interactions of PPI with other drugs.
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RESULTS AND DISCUSSION
Patient characteristics
The number of female patients was higher than men; the data included 
126 female patients (65.63%) and 66 male patients (34.38%) (Table 1). 
Women tended to maintain their weight and had an ideal body mass index 
by adjusting their dietary habits or diet. Regulated eating habits are crucial 
for gastric-acid secretion because these conditions allow the stomach to 
recognize feeding time so the stomach acid production can be controlled. 
This is the opposite of what occurs when a patient has an eating disorder 
where the production of stomach acid is excessive and irritates the mucosal 
wall of the stomach, which eventually causes nausea and pain.
Most of the patients who received PPI were over 65 years of age 
(89 patients; 46.35%). The aging process reduces the capacity of the 
gastric mucosa to protect against damage. This change was evident 
from the failure of the gastric mucosal barrier and increased risk of 
gastric and duodenal ulcers in the elderly, which was primarily due to 
nonsteroid anti-inflammation drug (NSAID) such as sodium diclofenac 
SAID. In addition, this change increased the incidence of gastric and 
duodenal ulcers in the elderly, induced by Helicobacter pylori [8].
PPI was most widely used for the treatment of diabetes mellitus (DM) 
type 2 (153 cases; 38.52%). DM type 2 was not the appropriate main 
indication for the use of PPI; however, DM is a systemic disease that 
could lead to dysfunction of various organs and impaired GI function. 
These problems were often encountered in patients with DM. Patients 
with diabetes often complain of the symptoms of upper GI disorders 
without any apparent cause. Particular tests could show a delay in 
emptying the stomach or diabetic gastroparesis, which commonly 
occur in people with DM types 1 and 2 [9]. Gastroparesis itself has been 
defined as the delayed emptying of the stomach characterized by a 
rapidly satiated, full feeling in the stomach, nausea, vomiting, bloating, 
and upper abdominal pain. These symptoms are similar to those of 
peptic ulcers and dyspepsia [10].
Most of the polycases were internal disease poly (80.75%), which is in 
accordance with the indication that PPI which is related to GI diseases.
Therapy
PPI drug classes
Lansoprazole was the most widely used PPI (76%) compared with 
omeprazole (24%), while rabeprazole, esomeprazole, and pantoprazole 
were not prescribed (Table 2). Based on information obtained from 
hospital personnel, lansoprazole and omeprazole were the only PPI 
provided for the Indonesian Universal Health Coverage patients 
in Gatot Soebroto Army Hospital. This was in accordance with the 
National Formulary in 2013 that the PPI included as anti-ulcer agents 
were lansoprazole and omeprazole [11].
PPI dose regimen
The most widely administered PPI dose regimen was 30 mg lansoprazole 
once daily (279 cases; 69.75%). Lansoprazole (30 mg) was also 
administered twice daily in 25 cases (6.25%). In this study, PPIs were used 
for two FDA-approved PPI-class drug indications, gastroesophageal reflux 
disease (GERD) and dyspepsia. This PPI dose regimen corresponded to 
the regimen listed in the 2014 National Drug Information in Indonesia 
where 30 mg lansoprazole once daily was recommended as the PPI for 
dyspepsia [12]. This also corresponded to the dosage of lansoprazole 
for dyspepsia in the National Institute For Health And Care Excellence 
Guidance on the management of dyspepsia, where lansoprazole may be 
administered at a standard dose of 30 mg once daily or at a high dose of 
30 mg twice daily [13]. Lansoprazole (30 mg) may also be given for GERD 
once or twice daily [14]. This dose may be used to treat gastric acid-
related diseases such as GERD, erosive esophagitis, peptic ulcer either 
associated with NSAID or H. pylori, and dyspepsia [12,15].
In 28 cases, 20 mg omeprazole was given once a day (7.00%) and 
twice a day in 68 cases (17.00%). For dyspepsia, 20 mg omeprazole 
can be administered once or twice daily [12,13]. For GERD, 20–40 mg 
omeprazole can be administered once daily or 20 mg can be 
administered twice daily [14,15]. Besides treating dyspepsia and GERD, 
this 20 mg dose of omeprazole can also be used to treat GI diseases, 
such as gastric ulcers and duodenal ulcers, H. pylori-related peptic 
ulcers, heartburn or stomach pain, and erosive esophagitis [12,15].
PPI administration duration
The administration duration of PPI is ≤4 weeks. This is in accordance 
with the drug information handbook, whereas the duration of 
PPI administration for GERD is omeprazole for up to 4 weeks and 
lansoprazole for up to 8 weeks [15]. According to the Indonesian 
agency of drug and food supervisory (BPOM), the duration of therapy 
with omeprazole or lansoprazole for dyspepsia is 2–4 weeks [12].
Table 1: Patient characteristics












Main diagnosis (n=400 prescriptions)
Non-insulin-dependent DM 153 38.52
Dyspepsia 68 17.00
Hypertension 64 16.00
Cardiovascular atherosclerosis 60 15.00
Renal failure 19 4.75
GERD 18 4.50
Stroke 8 2.00
Chronic thyroid disease 6 1.50
Chronic ischemia 4 1.00
Department (n=400 prescriptions)
Internal medicine 323 80.75
Cardiology and vascular medicine 71 17.75
Neurology 3 0.75
Pulmonology 3 0.75
DM: Diabetes mellitus, GERD: Gastroesophageal reflux disease
Table 2: PPI therapy
Therapy Quantity (n=400) Percentage (%)
PPI drug classes







1×30 mg 279 69.75
2×30 mg 25 6.25
Omeprazole
1×20 mg 28 7.00
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The rationale for the use of PPI
The result of the accuracy aspect of PPI were assessed from the patients’ 
condition, dosage, and indication, administration duration, and drug 
selection (Table 3) [7].
Appropriate assessment of patients’ condition
Of the 400 therapies with PPI treatment, all the patients met the 
exact criteria for an appropriate assessment of their condition. None 
of the patients had liver disorders, and there were no pregnant and 
breastfeeding patients that received a PPI that was not appropriate 
for their condition. Physiologically, the body of a pregnant woman will 
change in anatomy, physiology, and biochemistry as an adaptation to 
her pregnancy. Almost all the organ systems, including GI system, 
undergo physiological changes during pregnancy. GI complaints during 
pregnancy included vomiting, GERD, and constipation. PPI should be 
given in cases with persistent symptoms or when complications occur.
Omeprazole should not be given during pregnancy because it is category 
C drug, which causes teratogenic effects on the fetus, whereas other 
PPI classes are classified as B [16]. The use of PPI, either omeprazole, 
lansoprazole, rabeprazole, pantoprazole, or esomeprazole, should also 
be avoided in breastfeeding women [12].
The consumption of lansoprazole in patients with impaired liver function 
may lead to significantly decreased clearance and increased the area under 
the curve (AUC) and half-life of lansoprazole [17]. The use of omeprazole in 
patients with liver disorders also showed greater bioavailability; however, 
this does not occur in patients with renal impairment [18]. Due to the 
risk of drug accumulation in liver cirrhosis patients, special attention was 
required, and a dosage adjustment was necessary.
Appropriate indication
Of the 400 PPI therapies at Outpatients Installation of Gatot Soebroto 
Army Hospital from July to December 2015, 316 treatments (79.00%) 
were maintained to be appropriate indications, and the remaining 84 
therapies (21.00%) were not suitable. From the 84 unsuitable therapies 
indication of disease, 34 therapies were for non-insulin deficient--
(NID-DM) 29 were for cardiovascular atherosclerosis, ten were for 
hypertension, four were for renal failure, three were for stroke, three 
were for chronic thyroid problems, and one was for chronic ischemia. No 
other conditions that occurred in the patients required PPI therapy.
Several studies have shown that DM is a comorbid disease involving 
upper GI bleeding and is a risk factor for further bleeding. Changes 
in prostacyclin, which maintains the gastric mucosa, can occur in DM 
patients and can lead to increased bleeding. In cases related to DM 
type 2, the use of PPI was intended to overcome it [19].
Many patients had received antiplatelet therapy for various 
cardiovascular diseases. The use of these drugs causes major adverse 
events, such as bleeding complications in the GI tract. Aspirin, a standard 
antiplatelet therapy, was used in the prevention of cardiovascular 
disease. However, aspirin can still cause intestinal bleeding. In cases 
of the inappropriateness of cardiovascular disease, 14 cases were 
receiving aspirin. Over the past few decades, the use of PPI therapy has 
decreased the incidence of GI bleeding and has been used with aspirin 
to reduce such bleeding [20].
In cases of the inappropriateness of chronic ischemia, chronic thyroid, 
and hypertension, aspirin had been prescribed for these diseases. 
Aspirin works by inhibiting the cyclooxygenase enzyme that functions 
to convert arachidonic acid into endoperoxides and furthermore to be 
prostaglandins. Prostaglandins play an essential role in the regulation 
of HCl secretion from parietal cells and GI defenses, and thus, destroyed 
cytoprotection can cause mucosal injury, erosion, and ulcers. The use 
of PPI in these indications was intended to prevent the side effects of 
aspirin [21]. In addition, some patients complained of dyspepsia, and 
GERD and PPI were prescribed to treat them.
Appropriate dosage
Of the 400 therapies, there were 316 treatments (79.00%) deemed 
to have an appropriate dose, and 84 (21.00%) were unsuitable. The 
dosage of PPI given for dyspepsia varied, 30 mg lansoprazole was 
prescribed once or twice daily, or 20 mg omeprazole was prescribed 
once or twice daily. Based on the guidance of the PPI dosage used for 
dyspepsia, 20 mg omeprazole or 30 mg lansoprazole should only be 
administered once daily [12]. According to Patel and Dunn, the dosage 
of PPI used for dyspepsia was appropriate because three different doses 
of PPI could be used for dyspepsia, with standard, low, or high doses 
[13]. Standard doses are defined as one dose of 30 mg lansoprazole or 
20 mg omeprazole per day, a low dose was 15 mg lansoprazole or 10 mg 
omeprazole per day, and high doses were lansoprazole 30 mg twice per 
day or 40 mg omeprazole per day. For the initial symptoms of dyspepsia, 
patients may take high doses for 4 weeks and then proceeded with low 
doses if symptoms persist.
The dosage of PPI given for GERD also varied. Patients could be given 
30 mg lansoprazole once or twice daily or 20 mg omeprazole once 
or twice daily. According to Wolfe and Blunton, the dosage of PPI for 
GERD was appropriate as 30 mg lansoprazole could be administered 
once or twice a day or 20 mg omeprazole could be given once a day or 
40 mg twice a day [14]. Vanderhoff and Tahboub stated that PPI therapy 
for GERD could be given once or twice daily, and the doses could be 
reduced in accordance with the patients’ response [22].
From our analysis, it could be concluded that all the doses of PPI given 
for dyspepsia and GERD were appropriate. The inappropriate doses 
from 84 therapies (21.00) were because of an incorrect diagnosis; 
therefore, the inappropriate dose of PPI drugs was also ascertained.
Appropriate administration duration
Of the 400 therapies receiving PPI, 316 (79.00%) were deemed to have 
an appropriate administration duration, and the remaining 84 therapies 
(21.00%) were inappropriate. The longest duration of PPI administration 
was 4 weeks and appropriate according to the Drug Information Handbook 
and Indonesian National Drug Information [12,15]. The administration 
duration of PPI for GERD was omeprazole for up to 4 weeks and 
lansoprazole up to 8 weeks [15]. According to BPOM, the administration 
duration of omeprazole and lansoprazole for dyspepsia was 2–4 weeks 
[12]. According to Durand et al., the maximum recommended PPI 
treatment for almost all indications is 8 weeks [23]. Vanderhoff and 
Tahboub stated that the use of omeprazole and lansoprazole for 
<12 weeks is safe [22]. The 86 inappropriate administration duration 
cases were unsuitable diagnoses, and therefore, the administration 
duration of PPI was also considered inappropriate.
Table 3: The rational frequency for the use of PPI
Accuracy aspects Quantity (n=400) Percentage (%)
Appropriate Inappropriate Appropriate Inappropriate
Assessment of patient condition 400 0 100.00 0.00
Indication of disease 316 84 79.00 21.00
Dosage 316 84 79.00 21.00
Administration duration 316 84 79.00 21.00
Drug selection 335 65 83.75 16.25
PPI: Proton-pump inhibitor
 The 2nd Physics and Technologies in Medicine and Dentistry Symposium (PTMDS), Universitas Indonesia. Depok, Indonesia 361
Int J App Pharm, Vol 10, Special Issue 1, 2018
 Syafhan et al. 
Appropriate drug selection
Of the 400 patients receiving PPI, 335 (83.75%) were given an 
appropriate drug selection, and the remaining 65 (16.25%) were 
inappropriate. In 22 cases, there were drug interactions between the 
PPI and other drugs, including the interaction between omeprazole and 
lansoprazole with clopidogrel. The remaining 33 cases were determined 
to be inappropriate drug selections because the PPI prescribed was not 
in accordance with the indication.
Clopidogrel was used as antiplatelet therapy for acute coronary patients 
and in patients undergoing percutaneous intervention, which has been 
associated with an increased risk of GI bleeding. PPI has been used with 
clopidogrel to reduce the risk of GI bleeding. The use of clopidogrel 
with omeprazole and/or lansoprazole may lead to drug interactions. 
Clopidogrel is a prodrug that must be activated through the metabolism 
of CYP450, mainly through isoenzyme CYP2C19, to convert the prodrug 
to a thiol derivative in its active form. Omeprazole and lansoprazole are 
metabolized through the same pathway, thus leading to competition 
between clopidogrel and omeprazole and lansoprazole. This interaction 
inhibits the change of clopidogrel to its active form which reduces the 
effectiveness of the therapy [24].
Rabeprazole is primarily metabolized in a non-enzymatic way to be 
thioether rabeprazole which is a weak inhibitor in CYP2C19 compared 
with omeprazole; thus, rabeprazole is the PPI that may be used when 
taken with clopidogrel [25]. Based on other studies, pantoprazole was 
also recommended as a safer therapy prescribed with clopidogrel 
compared with other PPI because there were fewer interactions 
between clopidogrel and pantoprazole [26].
PPI drug interactions
Drug interactions with PPI were found in 324 prescriptions (81.00%) of 
400 in 475 cases (Table 4). Major interactions were identified in 42 cases 
consisting of interactions between lansoprazole and omeprazole with 
mycophenolate mofetil (MMF), cilostazol, and clopidogrel. Moderate 
interactions were identified in 138 cases consisting of interactions between 
lansoprazole and omeprazole with warfarin, iron, propranolol, simvastatin, 
atorvastatin, and levothyroxine as well as interactions of omeprazole with 
cyclosporine. Minor interactions were identified in 295 cases consisting 
of interactions between lansoprazole and omeprazole with sucralfate, 
antacid, and cyanocobalamin, as well as lansoprazole with theophylline.
Major interactions
The interaction of MMF with PPI caused a decrease in MMF active 
metabolite exposure, increasing the risk of failure of MMF, therapy 
including acute rejection after transplantation. Increased intragastric 
pH due to the use of PPI caused a decrease in MMF dissolution resulting 
in decreased MMF absorption [27]. MMF doses need to be increased to 
1.5 g twice daily to achieve immunosuppressive effects equivalent to 
standard doses when administered with PPI [28].
Omeprazole and lansoprazole are competitive inhibitors of CYP2C19 
metabolism enzymes. The CYP2C19 enzyme is responsible for the 
metabolism of cilostazol. Therefore, the inhibition of the enzyme by 
lansoprazole or omeprazole may lead to an increase in the concentration 
of cilostazol and the potential for an antiplatelet effect from cilostazol. 
The dose of cilostazol could be reduced if there was evidence of an 
increase in plasma concentrations of cilostazol during the monitoring 
of drug plasma concentrations [29]. Clopidogrel undergoes conversion 
to its active form with the help of the CYP2C19 enzyme. Inhibition of the 
CYP2C19 enzyme by lansoprazole or omeprazole causes a significant 
decrease in the Cmax and AUC from the clopidogrel active metabolite. 
Therefore, the antiplatelet activity of clopidogrel decreases and causes 
an increased risk of thrombotic events [30]. PPI, such as pantoprazole, 
can lower the inhibition effect of CYP2C19 [31].
Moderate interactions
The interaction of warfarin with PPI occurs through the inhibition of 
CYP2C19 metabolism enzymes competitively by lansoprazole and 
omeprazole, leading to decreased warfarin metabolism, especially 
R-warfarin. Monitoring the patient’s international normalized ratio 
levels can be done when the combination of the drugs cannot be avoided. 
Warfarin dose adjustments can be performed when necessary to 
maintain the expected anticoagulation levels [32]. Similar results have 
also been found with the combined use of propranolol with lansoprazole 
or omeprazole [33]. Metabolic inhibition leads to increased propranolol 
exposure and toxicity. When propranolol is used in conjunction with 
omeprazole or lansoprazole, it is necessary to measure propranolol 
toxic effects, such as bradycardia and hypotension, in patients [33].
An increased intragastric pH due to the use of PPI caused a decrease 
in levothyroxine absorption, resulting in a decrease in efficacy 
characterized by increased thyroid-stimulating hormone (TSH) levels 
of patients. The strict monitoring of TSH levels and levothyroxine dose 
adjustments is necessary for patients receiving levothyroxine therapy 
with PPI [34]. Increased intragastric pH also affects iron absorption 
rates, leading to a decrease in iron bioavailability. Patients with an iron 
deficiency who are given PPI therapy may be treated with high-dose 
iron therapy for longer periods or with intravenous iron therapy [35].
PPIs, such as lansoprazole and omeprazole, are competitive inhibitors 
of P-glycoprotein efflux transporters. The combined use of omeprazole 
or lansoprazole with a P-glycoprotein transporter substrate, such as 
statin drugs, may decrease the drug secretion to the intestinal lumen, so 
the bioavailability of simvastatin or atorvastatin increases. This leads to 
an increased risk of drug toxicity such as myalgia, myositis, myopathy, 
or rhabdomyolysis. If the patient received statin drug therapy with PPI, 
monitoring of these toxic effects should be undertaken [36-39].
The combined use of cyclosporine with omeprazole showed 
interactions in the cyclosporine metabolic stage; however, the 
interaction effect on cyclosporine concentrations remains unclear. In 
one case review, both increased and decreased levels of cyclosporine 
had been found. Monitoring cyclosporine concentrations in the blood 
Table 4: Identified PPI drug interactions (n=475 cases)
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may be performed in patients receiving therapy with cyclosporine and 
omeprazole. Adjustments to cyclosporine doses may also be performed 
when necessary [40,41].
Minor interactions
The interaction between PPI and cyanocobalamin is minor, where the 
effect of this interaction was the decrease in cyanocobalamin absorption 
caused by increased intragastric pH during PPI therapy. Possible 
management of this interaction include replacing the anti-ulcer therapy 
with ranitidine, famotidine, or sucralfate, providing that they are taken 
about 2 h apart, or cyanocobalamin is administered intramuscularly or 
subcutaneously [42].
Sucralfate leads to an increased secretion of mucus-rich bicarbonate 
ions and provides buffer effects in the mucosal region. This leads to 
decreased protonation and conversion of PPI into its active form, 
thereby reducing the effectiveness of PPI. This interaction could be 
prevented by giving PPI 1 h before sucralfate. Similar interactions were 
also found in the combined use of PPI and antacids [43].
Interactions with minor severity subsequently occurred between 
theophylline and lansoprazole, which caused a decrease in serum 
theophylline concentrations. The interaction occurred through the 
induction of theophylline metabolism enzyme CYP1A2 by lansoprazole, 
which caused an increase in theophylline clearance. Management could 
be done through monitoring the serum concentrations of theophylline 
and adjusting the theophylline dose when necessary [44].
CONCLUSION
Based on this study, the use of PPI in patients at the Outpatient 
Installation Gatot Soebroto Army Hospital from July to December 2015 
was not completely appropriate and had great potential for interactions 
with other drugs.
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